M.A. Zocco
Sapienza University of Rome
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M.A. Zocco.
Alimentary Pharmacology & Therapeutics | 2006
M.A. Zocco; L. Zileri Dal Verme; Filippo Cremonini; A.C. Piscaglia; E.C. Nista; Marcello Candelli; M. Novi; Donato Rigante; I. A. Cazzato; Veronica Ojetti; Alessandro Armuzzi; Giovanni Gasbarrini; Antonio Gasbarrini
Aminosalicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative colitis. The rationale for using probiotics is based on the evidence implicating intestinal bacteria in the pathogenesis of this disorder.
Journal of Hepatology | 2009
M.A. Zocco; Enrico Di Stasio; Raimondo De Cristofaro; M. Novi; M.E. Ainora; Francesca Romana Ponziani; Laura Riccardi; Stefano Lancellotti; Angelo Santoliquido; Roberto Antonio Flore; Maurizio Pompili; Gian Ludovico Rapaccini; Paolo Tondi; Giovanni Gasbarrini; Raffaele Landolfi; Antonio Gasbarrini
BACKGROUND/AIMS Prognostic scores currently used in cirrhotic patients do not include thrombotic risk factors (TRFs). Predicting factors of portal vein thrombosis (PVT) development are still unknown. We wanted to describe TRFs as a function of liver disease severity using the MELD score and assess the role of local and systemic TRFs as predictors of PVT development in cirrhotic patients. METHODS One hundred consecutive patients with liver cirrhosis were included in the study. TRFs, D-dimers, MELD score, portal vein patency and flow velocity were evaluated in all subjects at baseline and every 6 months thereafter. Variables able to predict PVT development within 1 year were identified by means of multiple logistic regression. RESULTS The plasma levels of protein C and antithrombin were lower and the concentration of D-dimers was higher in patients with advanced disease. Plasma levels of antithrombin, protein C and protein S resulted significantly lower in PVT group at univariate analysis, but reduced portal vein flow velocity was the only variable independently associated with PVT development. CONCLUSIONS Lower concentrations of natural coagulation inhibitors are frequently detected in patients with liver cirrhosis. A reduced portal flow velocity seems to be the most important predictive variable for PVT development in patients with cirrhosis.
Alimentary Pharmacology & Therapeutics | 2000
Giovanni Cammarota; Rossella Cianci; Oreste Cannizzaro; L. Cuoco; G. Pirozzi; Antonio Gasbarrini; Alessandro Armuzzi; M.A. Zocco; Luca Santarelli; F. Arancio; Giovanni Gasbarrini
One‐week low‐dose proton pump inhibitor‐based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection.
Alimentary Pharmacology & Therapeutics | 2004
E.C. Nista; Marcello Candelli; Filippo Cremonini; Immacolata A. Cazzato; M.A. Zocco; Francesco Franceschi; Giovanni Cammarota; Giovanni Gasbarrini; Antonio Gasbarrini
Background : Helicobacter pylori eradication fails in about 10% of patients, particularly because of the occurrence of resistance to antibiotics and side‐effects. During anti‐H. pylori therapy, probiotics have been successfully used to reduce the incidence of side‐effects.
Alimentary Pharmacology & Therapeutics | 2002
Alessandro Armuzzi; Marcello Candelli; M.A. Zocco; A. Andreoli; A. De Lorenzo; E.C. Nista; Luca Miele; Filippo Cremonini; Immacolata A. Cazzato; Antonio Grieco; Giovanni Gasbarrini; Antonio Gasbarrini
Carbon‐labelled breath tests were proposed as tools for the evaluation of human liver function 30 years ago, but have never become part of clinical routine. One reason for this is the complex role of the liver in metabolic regulation, making it difficult to provide essential information for the management of patients with liver disease with a single test and to satisfy the hepatology community. As a result, a battery of breath tests have been developed. Depending on the test compound administered, different metabolic pathways (microsomal, cytosolic, mitochondrial) can be examined. Most available data come from microsomal function tests, whilst information about cytosolic and mitochondrial liver function is more limited. However, breath tests have shown promise in some studies, in particular to predict the outcome of patients with chronic liver disease or to monitor hepatic function after treatment. Whilst we await new substrates that can be used to measure liver function in a more valid manner, and large prospective studies to assess the usefulness of available test compounds, the aim of this review is to describe how far we have come in this controversial and unresolved issue.
Alimentary Pharmacology & Therapeutics | 2003
E.C. Nista; Marcello Candelli; Filippo Cremonini; Immacolata A. Cazzato; S. Di Caro; Maurizio Gabrielli; Luca Santarelli; M.A. Zocco; Veronica Ojetti; Emilia Carloni; Giovanni Cammarota; Giovanni Gasbarrini; Antonio Gasbarrini
Background : Levofloxacin has been shown to be effective in Helicobacter pylori eradication. Two 10‐day levofloxacin‐based triple therapies were compared with standard 7‐ and 14‐day quadruple regimens in second‐line treatment.
Helicobacter | 2003
Hans-Olof Nilsson; Antonio Pietroiusti; Maurizio Gabrielli; M.A. Zocco; Giovanni Gasbarrini; Antonio Gasbarrini
The involvement of Helicobacter pylori in the pathogenesis of extragastric diseases continues to be an interesting topic in the field of Helicobacter‐related pathology.
Movement Disorders | 2013
Alfonso Fasano; Francesco Bove; Maurizio Gabrielli; Martina Petracca; M.A. Zocco; Enzo Ragazzoni; Federico Barbaro; Carla Piano; Serena Fortuna; Annalisa Tortora; Raffaella Di Giacopo; Mariachiara Campanale; G. Gigante; Ernesto Cristiano Lauritano; Pierluigi Navarra; Stefano Marconi; Antonio Gasbarrini; Anna Rita Bentivoglio
Parkinsons disease is associated with gastrointestinal motility abnormalities favoring the occurrence of local infections. The aim of this study was to investigate whether small intestinal bacterial overgrowth contributes to the pathophysiology of motor fluctuations. Thirty‐three patients and 30 controls underwent glucose, lactulose, and urea breath tests to detect small intestinal bacterial overgrowth and Helicobacter pylori infection. Patients also underwent ultrasonography to evaluate gastric emptying. The clinical status and plasma concentration of levodopa were assessed after an acute drug challenge with a standard dose of levodopa, and motor complications were assessed by Unified Parkinsons Disease Rating Scale–IV and by 1‐week diaries of motor conditions. Patients with small intestinal bacterial overgrowth were treated with rifaximin and were clinically and instrumentally reevaluated 1 and 6 months later. The prevalence of small intestinal bacterial overgrowth was significantly higher in patients than in controls (54.5% vs. 20.0%; P = .01), whereas the prevalence of Helicobacter pylori infection was not (33.3% vs. 26.7%). Compared with patients without any infection, the prevalence of unpredictable fluctuations was significantly higher in patients with both infections (8.3% vs. 87.5%; P = .008). Gastric half‐emptying time was significantly longer in patients than in healthy controls but did not differ in patients based on their infective status. Compared with patients without isolated small intestinal bacterial overgrowth, patients with isolated small intestinal bacterial overgrowth had longer off time daily and more episodes of delayed‐on and no‐on. The eradication of small intestinal bacterial overgrowth resulted in improvement in motor fluctuations without affecting the pharmacokinetics of levodopa. The relapse rate of small intestinal bacterial overgrowth at 6 months was 43%.
European Journal of Gastroenterology & Hepatology | 2002
Simona Di Caro; M.A. Zocco; Filippo Cremonini; Marcello Candelli; E.C. Nista; Francesco Bartolozzi; Alessandro Armuzzi; Giovanni Cammarota; Luca Santarelli; Antonio Gasbarrini
Background A 7 day treatment scheme based on rabeprazole/levofloxacin/amoxycillin or tinidazole achieved an eradication rate over 90%. However, the combination of drugs and duration of treatment for the correct use of levofloxacin in the eradication of Helicaobacter pylori are still unclear. Objective To compare the efficacy and tolerability of rabeprazole/levofloxacin based dual therapies given for 5, 7 or 10 days with rabeprazole/levofloxacin/amoxycillin triple therapy for 7 days. Methods One hundred and sixty patients with H. pylori infection documented by the 13C-urea breath test and histology were included in this prospective, open label study. Subjects were randomized in four groups: (1) levofloxacin (500 mg o.d.), amoxycillin (1 g b.d.) and rabeprazole (20 mg o.d.) for 7 days; (2) levofloxacin (500 mg o.d.) and rabeprazole (20 mg o.d.) for 5 days; (3) levofloxacin (500 mg o.d.) and rabeprazole (20 mg o.d.) for 7 days; and (4) levofloxacin (500 mg o.d.) and rabeprazole (20 mg o.d.) for 10 days. Six weeks after the end of therapy H. pylori status was checked by using the 13C-urea breath test. Results All patients completed the therapeutic regimens. The eradication rate was not significantly modified by treatment duration in the dual therapy schemes (5 days: 20/40, 50%; 7 days: 28/40, 70%; 10 days: 26/40, 65%). The eradication rate of the 1 week levofloxacin based triple therapy was significantly higher than that observed using any dual therapies (36/40). No major adverse effects were observed. Conclusions A rabeprazole/levofloxacin dual eradication regimen is simple and well tolerated but does not achieve an acceptable eradication rate when compared to a 1 week rabeprazole/levofloxacin/amoxycillin triple therapy. The eradication rate did not increase with a longer regimen.
The American Journal of Gastroenterology | 2006
E.C. Nista; Marcello Candelli; M.A. Zocco; Filippo Cremonini; Veronica Ojetti; R. Finizio; Cristiano Spada; Giovanni Cammarota; Giovanni Gasbarrini; Antonio Gasbarrini
BACKGROUND:The standard first-line therapies for Helicobacter pylori eradication are based on clarithromycin and amoxicillin or metronidazole. Recent studies suggested levofloxacin as an alternative option for both first-and second-line H. pylori eradication treatment.AIMS:To compare efficacy and tolerability of two different 7-day standard triple therapies versus 7-day levofloxacin-based triple therapy in first-line treatment for H. pylori infection.METHODS:Three hundred consecutive H. pylori positive patients were randomized to receive: clarithromycin, amoxicillin, esomeprazole (Group A: N = 100); clarithromycin, metronidazole, esomeprazole (Group B: N = 100); or clarithromycin, levofloxacin, esomeprazole (Group C: N = 100). H. pylori status was rechecked by 13C urea breath test 6 wk after the end of therapy.RESULTS:Sixteen out of 300 patients discontinued treatment because of the occurrence of side effects (Group A, 5; Group B, 7; Group C, 4). The eradication rates in intention to treat (ITT) and per protocol (PP) analyses were: Group A, 75% and 79%; Group B, 72% and 77.4%; and Group C, 87% and 90.6%. The eradication rate achieved with levofloxacin-based triple therapy was significantly higher than that with standard therapies in either ITT (87% vs 75%, p <0.05; 87% vs 72%, p <0.01;) or PP analysis (90.6% vs 79%, p <0.05; 90.6 vs 77.4, p <0.05). No difference was found between standard triple therapies. The incidence of side effects was similar among groups.CONCLUSIONS:A 7-day levofloxacin-based triple therapy can achieve higher H. pylori eradication rates than standard regimens. These data suggest levofloxacin-based regimens can be the most effective in first-line anti-H. pylori therapy, at least in the Italian population.